A Randomized Clinical Study of Geiftinib and Pemetrexed as Second Line Therapy for Advanced Non-squamous Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2013.08.03
- VernacularTitle:吉非替尼对比培美曲塞二线治疗晚期非鳞型非小细胞肺癌的随机对照临床研究
- Author:
DAI HONGYU
1
;
XU LING
;
XIA CHUNWEI
;
CHEN WENPING
Author Information
1. 南京市胸科医院呼吸科
- Keywords:
Geiftinib;
Pemetrexed;
Lung neoplasms
- From:
Chinese Journal of Lung Cancer
2013;(8):405-410
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Geiftinib and Pemetrexed are drugs used as second-line therapy for ad-vanced non-small cell lung cancer (NSCLC), although studies comparing the two drugs are limited. hTe aim of this study is to explore the effects, safety, and quality of life (QoL) of Geiftinib and Pemetrexed on patients with advanced non-squamous NSCLC. Methods Forty-six advanced non-squamous NSCLC patients who failed to ifrst-line therapy were randomly divided into two groups with 23 patients each, one using oral Geiftinib (Geiftinib group) and the other using intravenous injection Pemetrexed (Pemetrexed group). hTe effects, safety, and QoL were determined and analyzed. Results For the Pemetrexed group, objective response rate (ORR) was 13.0%(3/23), disease control rate (DCR) was 30.4%(7/23), and median progres-sion-free survival (mPFS) was 3.1 months. In the Geiftinib group, ORR was 17.3%(4/23), DCR was 39.1%(9/23), and mPFS was 4.4 months. Compared with the Pemetrexed group, the ORR, DCR, and mPFS in the Geiftinib group exhibited no statisti-cal signiifcance (P>0.05). Furthermore, the most common toxicities in the Pemetrexed group were neutropenia (n=9, 39.13%) and fatigue (n=8, 34.78%), whereas those in the in Geiftinib group were skin rash (n=8, 34.78%) and diarrhea (n=4, 17.39%). Compared with baseline, the QoL improved in both groups but to different degrees. Likewise, emotional, functional well-being, and QoL aspects speciifcally related to lung cancer were better improved in the Geiftinib group than in the Pemetrexed group (P<0.05). Conclusion hTe effects of Pemetrexed and Geiftinib as second line therapy were similar, although with dif-ferent AEs. Both drugs could improve the QoL, but Geiftinib showed better overall results than Pemetrexed.
